{"id":61570,"date":"2026-03-27T15:49:08","date_gmt":"2026-03-27T07:49:08","guid":{"rendered":"https:\/\/flcube.com\/?p=61570"},"modified":"2026-03-27T15:49:09","modified_gmt":"2026-03-27T07:49:09","slug":"c-ray-therapeutics-partners-with-shine-technologies-lu-177-supply-agreement-targets-china-radiopharmaceutical-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61570","title":{"rendered":"C-Ray Therapeutics Partners with SHINE Technologies \u2013 Lu-177 Supply Agreement Targets China Radiopharmaceutical Market"},"content":{"rendered":"\n

C-Ray Therapeutics<\/strong>, a Chengdu-based radiopharmaceuticals specialist<\/strong>, announced a master radioisotope supply agreement<\/strong> with SHINE Technologies, LLC<\/strong>, a U.S. nuclear technology company<\/strong>. SHINE will supply carrier-free Lu-177<\/strong> meeting GMP standards<\/strong> and China\/U.S. regulatory requirements<\/strong> on a long-term basis<\/strong>, with C-Ray serving as SHINE’s exclusive distribution partner in mainland China<\/strong> for this critical therapeutic medical isotope<\/strong> used in targeted radionuclide therapy<\/strong> for prostate cancer and neuroendocrine tumors (NETs)<\/strong>.<\/p>\n\n\n\n

Partnership Framework<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>C-Ray Therapeutics (China) + SHINE Technologies, LLC (U.S.)<\/td><\/tr>
Agreement Type<\/strong><\/td>Master radioisotope supply agreement (long-term)<\/td><\/tr>
Product<\/strong><\/td>Carrier-free Lu-177 (lutetium-177)<\/strong><\/td><\/tr>
Quality Standards<\/strong><\/td>GMP-compliant<\/strong>; meets China NMPA and U.S. FDA requirements<\/strong><\/td><\/tr>
Distribution Rights<\/strong><\/td>C-Ray: Exclusive mainland China distributor<\/strong> for SHINE Lu-177<\/td><\/tr>
Target Customers<\/strong><\/td>Chinese radiopharmaceutical companies, biotech firms, medical institutions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Lu-177: Therapeutic Medical Isotope Profile<\/h2>\n\n\n\n
Attribute<\/th>Lu-177 Specification<\/th>Clinical Application<\/th><\/tr><\/thead>
Physical Half-Life<\/strong><\/td>6.7 days<\/strong> \u2013 optimal for therapy logistics and patient dosing<\/td>Allows centralized production<\/strong> and regional distribution<\/strong><\/td><\/tr>
Beta-Ray Energy<\/strong><\/td>Medium-energy beta emissions<\/strong> (0.497 MeV max)<\/td>Effective tumor cell killing<\/strong> with limited tissue penetration (tumor-specific cytotoxicity)<\/td><\/tr>
Imaging Capability<\/strong><\/td>Gamma emissions<\/strong> (208 keV) enable SPECT imaging<\/strong><\/td>Theranostic<\/strong> approach \u2013 simultaneous therapy and treatment monitoring<\/td><\/tr>
Primary Indications<\/strong><\/td>Prostate cancer<\/strong> (PSMA-targeting), neuroendocrine tumors (NETs)<\/strong><\/td>Lutathera (Novartis)<\/strong> established market; Pluvicto (Novartis)<\/strong> driving prostate cancer adoption<\/td><\/tr>
Global Utilization<\/strong><\/td>Most widely used therapeutic medical nuclide<\/strong> in targeted radionuclide therapy<\/td>$2+ billion annual market<\/strong> growing at 20%+ CAGR<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Impact<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Radiopharmaceutical Gap<\/strong><\/td>Domestic Lu-177 production limited<\/strong> \u2013 reliance on imports from Russia, South Africa, Australia; supply security risk<\/strong> for growing theranostics market<\/td><\/tr>
SHINE Technology Advantage<\/strong><\/td>U.S.-based accelerator production<\/strong> \u2013 carrier-free Lu-177<\/strong> (higher specific activity vs. reactor-produced); GMP quality<\/strong> supports regulatory filings<\/td><\/tr>
C-Ray Distribution Network<\/strong><\/td>Exclusive China rights<\/strong> \u2013 positions as critical infrastructure provider<\/strong> for 50+ radiopharmaceutical developers<\/strong> and 300+ nuclear medicine centers<\/strong><\/td><\/tr>
Theranostics Market Growth<\/strong><\/td>China PSMA-targeting and NET therapies<\/strong> expanding rapidly; Lu-177 demand<\/strong> projected 3x increase 2025\u20132028<\/strong><\/td><\/tr>
Geopolitical Consideration<\/strong><\/td>U.S.-China nuclear materials trade<\/strong> requires strict export controls<\/strong>; agreement demonstrates compliance pathway<\/strong> for medical isotope commerce<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n